2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor sizeDiagnosing Anal Squamous Intraepithelial Lesions With and Without p16: An Interobserver Variability Study.
Krishnamurti U, Mohammad M, Monsrud A, Mosunjac M, Oprea G, Hanley K, Tadros T, Flowers L, Mosunjac M. Diagnosing Anal Squamous Intraepithelial Lesions With and Without p16: An Interobserver Variability Study. Journal Of Lower Genital Tract Disease 2020, 24: 69-74. PMID: 31860579, DOI: 10.1097/lgt.0000000000000500.Peer-Reviewed Original Research
2019
A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatients
2016
CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition
Kapur N, Mir H, Clark III C, Krishnamurti U, Beech D, Lillard J, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. British Journal Of Cancer 2016, 114: 1343-1351. PMID: 27149649, PMCID: PMC4984452, DOI: 10.1038/bjc.2016.113.Peer-Reviewed Original ResearchConceptsColon cancerNodal statusCCR6 expressionTherapeutic optionsEMT markersExpression of CCR6Node-positive casesTNM staging systemUndefined molecular mechanismsPotential therapeutic targetNormal adjacent tissuesTissues/cellsMolecular mechanismsIdentification of markersAdjuvant chemotherapyAdvanced diseaseMolecular pathwaysDistant metastasisN-cadherinClinical associationsStaging systemMetastatic casesInvasive potentialΒ-cateninCancer cases
2015
GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology
Deftereos G, Ramirez A, Silverman J, Krishnamurti U. GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology. The American Journal Of Surgical Pathology 2015, 39: 1282-1289. PMID: 26274030, DOI: 10.1097/pas.0000000000000505.Peer-Reviewed Original ResearchConceptsTriple-negative breast carcinomaGCDFP-15Breast carcinomaCytology casesGynecologic malignanciesER expressionHistologic subtypeExpression correlatesMetastatic gynecologic malignanciesMetastatic breast carcinomaNegative breast carcinomaPrimary breast carcinomaStaining scoresNegative carcinomasOvarian carcinomaImmunohistochemistry expressionHistology casesMammaglobinCarcinomaIntensity scoresGATA3 expressionSubtypesGATA3Cancer cellsBreast
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapy
2011
Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research
Miguel R, Chivukula M, Krishnamurti U, Amortegui A, Kant J, Sweet R, Wiesenfeld H, Phillips J, Cherpes T. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research. Pathology - Research And Practice 2011, 207: 680-685. PMID: 21996319, PMCID: PMC3215901, DOI: 10.1016/j.prp.2011.08.007.Peer-Reviewed Original ResearchConceptsHistologic endometritisPlasma cellsInflammatory disease researchLower riskEndometrial leukocyte subpopulationsEndometrial biopsy specimensAdditional immunohistochemical analysisDisease researchEndometrial neutrophilsChronic endometritisEndometrial biopsyInflammatory infiltrateConventional criteriaBiopsy specimensInflammatory processLeukocyte subpopulationsImmunohistochemical analysisEndometritisCytometric analysisWomenPID developmentCellsRiskInfiltratesBiopsyEndometrial leukocyte subpopulations associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis genital tract infection
Reighard S, Sweet R, Miguel C, Miguel R, Chivukula M, Krishnamurti U, Cherpes T. Endometrial leukocyte subpopulations associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis genital tract infection. American Journal Of Obstetrics And Gynecology 2011, 205: 324.e1-324.e7. PMID: 21777898, PMCID: PMC3204313, DOI: 10.1016/j.ajog.2011.05.031.Peer-Reviewed Original ResearchConceptsEndometrial leukocyte subpopulationsC trachomatisLeukocyte subpopulationsN gonorrhoeaeT cellsT vaginalisChlamydia trachomatisB cellsNeisseria gonorrhoeaeEndometrial T cellsRobust inflammatory infiltrateGenital tract infectionT vaginalis infectionGenital tract pathogensPlasma cell numbersHost inflammatory responseInflammatory disease developmentUninfected womenTract infectionsInflammatory infiltrateTract pathogensVaginalis infectionInflammatory processEndocervical infectionInflammatory responseCorrelation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2011, 19: 28-32. PMID: 20823770, DOI: 10.1097/pai.0b013e3181e9bb6f.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 amplificationReceptor negativityPrognostic indicatorNottingham scoreBreast cancerNeck squamous cell carcinomaNonsmall cell lung carcinomaHormone receptor negativityAdverse prognostic indicatorEstrogen receptor negativitySquamous cell carcinomaIndependent prognostic indicatorCell lung carcinomaCell carcinomaP53 positivityBladder carcinomaP53 immunostainingP53 overexpressionImmunohistochemical expressionLung carcinomaCarcinomaP53 expression
2009
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Krishnamurti U, Hammers J, Atem F, Storto P, Silverman J. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Modern Pathology 2009, 22: 1044-1048. PMID: 19396150, DOI: 10.1038/modpathol.2009.61.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 gene amplificationBreast cancerChromosome 17 aneusomyHuman epidermal growth factor receptor 2 (HER2) oncoproteinAdverse prognostic factorAdverse prognostic indicatorEstrogen receptor negativityTreatment of patientsHigh nuclear gradePoor prognostic significanceGene amplificationPaucity of literatureReceptor negativityMost patientsPathologic factorsPrognostic factorsPredictive factorsPrognostic significanceHistologic gradePrognostic indicatorTumor stageHER2 overexpression